Clinical experiences with systemically administered siRNA-based therapeutics in cancer
Crossref DOI link: https://doi.org/10.1038/nrd4685
Published Online: 2015-11-16
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Zuckerman, Jonathan E.
Davis, Mark E.
Text and Data Mining valid from 2015-11-16
Article History
First Online: 16 November 2015
Competing interests
: M.E.D. has stock in and is a consultant to Cerulean Pharma, Avidity NanoMedicines and Intellia Therapeutics.